17 research outputs found

    Reduced fire severity offers near-term buffer to climate-driven declines in conifer resilience across the western United States

    Get PDF
    Increasing fire severity and warmer, drier postfire conditions are making forests in the western United States (West) vulnerable to ecological transformation. Yet, the relative importance of and interactions between these drivers of forest change remain unresolved, particularly over upcoming decades. Here, we assess how the interactive impacts of changing climate and wildfire activity influenced conifer regeneration after 334 wildfires, using a dataset of postfire conifer regeneration from 10,230 field plots. Our findings highlight declining regeneration capacity across the West over the past four decades for the eight dominant conifer species studied. Postfire regeneration is sensitive to high-severity fire, which limits seed availability, and postfire climate, which influences seedling establishment. In the near-term, projected differences in recruitment probability between low- and high-severity fire scenarios were larger than projected climate change impacts for most species, suggesting that reductions in fire severity, and resultant impacts on seed availability, could partially offset expected climate-driven declines in postfire regeneration. Across 40 to 42% of the study area, we project postfire conifer regeneration to be likely following low-severity but not high-severity fire under future climate scenarios (2031 to 2050). However, increasingly warm, dry climate conditions are projected to eventually outweigh the influence of fire severity and seed availability. The percent of the study area considered unlikely to experience conifer regeneration, regardless of fire severity, increased from 5% in 1981 to 2000 to 26 to 31% by mid-century, highlighting a limited time window over which management actions that reduce fire severity may effectively support postfire conifer regeneration. © 2023 the Author(s)

    Quantifying and Predicting the Effect of Exogenous Interleukin-7 on CD4+T Cells in HIV-1 Infection

    No full text
    International audienceExogenous Interleukin-7 (IL-7), in supplement to antiretroviral therapy, leads to a substantial increase of all CD4+ T cell subsets in HIV-1 infected patients. However, the quantitative contribution of the several potential mechanisms of action of IL-7 is unknown. We have performed a mathematical analysis of repeated measurements of total and naive CD4+ T cells and their Ki67 expression from HIV-1 infected patients involved in three phase I/II studies (N = 53 patients). We show that, besides a transient increase of peripheral proliferation, IL-7 exerts additional effects that play a significant role in CD4+ T cell dynamics up to 52 weeks. A decrease of the loss rate of the total CD4+ T cell is the most probable explanation. If this effect could be maintained during repeated administration of IL-7, our simulation study shows that such a strategy may allow maintaining CD4+ T cell counts above 500 cells/µL with 4 cycles or fewer over a period of two years. This in-depth analysis of clinical data revealed the potential for IL-7 to achieve sustained CD4+ T cell restoration with limited IL-7 exposure in HIV-1 infected patients with immune failure despite antiretroviral therapy

    Clinical trials and management of osteochondral lesions

    No full text
    Osteochondral lesions are frequent and important causes of pain and disability. These lesions are induced by traumatic injuries or by diseases that affect both the cartilage surface and the subchondral bone. Due to the limited cartilage ability to regenerate and self-repair, these lesions tend to gradually worsen and progress towards osteoarthritis. The clinical, social, and economic impact of the osteochondral lesions is impressive and although therapeutic alternatives are under discussion, a consensus is not yet been achieved. Over the previous decade, new strategies based on innovative tissue engineering approaches have been developed with promising results. However, in order those products reach the market and help the actual patient in an effective manner, there is still a lot of work to be done. The current state of the implications, clinical aspects, and available treatments for this pathology, as well as the ongoing preclinical and clinical trials are presented in this chapter.A. da Silva Morais acknowledges ERC-2012-ADG 20120216–321266 (ComplexiTE) for his Postdoc scholarship. Thanks to the project FROnTHERA (NORTE-01- 0145-FEDER-000023), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). The financial support from the Portuguese Foundation for Science and Technology for the M-ERA-NET/0001/2014 “HierarchiTech” project and for the funds provided under the program Investigador FCT 2012, 2014, and 2015 (IF/00423/2012, IF/01214/2014, and IF/01285/2015) is also greatly acknowledged.info:eu-repo/semantics/publishedVersio

    Epidemiology of Chronic Pruritus: Where Have We Been and Where Are We Going?

    No full text
    Between 23 and 44 million Americans are estimated to suffer from chronic pruritus in the setting of both cutaneous and systemic conditions. Patients with chronic pruritus suffer extreme detriment to their ability to function, including but not limited to deranged sleep patterns, mood disturbances, increased levels of anxiety and depression, and reduced levels of overall quality of life. Indeed, chronic pruritus is now known to be as debilitating as chronic pain. For these reasons, chronic pruritus represents a serious public health concern that must be adequately addressed by clinicians. We present an up-to-date summary of the epidemiology of chronic itch in different cutaneous and systemic conditions. While we have endeavored to discuss some of the most common causes of chronic pruritus, this review does not encompass all of the myriad different diseases in which chronic pruritus can occur
    corecore